

## WEST Search History

DATE: Wednesday, September 26, 2007

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
<i>DB=PGPB,USPT; PLUR=YES; OP=ADJ</i>			
<input type="checkbox"/>	L20	L18 and ZD6126	5
<input type="checkbox"/>	L19	L18 and N-acetylcolchinol	2
<input type="checkbox"/>	L18	514/49.icls. or 514/49.ccls. or 514/511.icls. or 514/511.ccls..	1007
<input type="checkbox"/>	L17	fluorouracil.ab. and prodrug.ab.	8
<input type="checkbox"/>	L16	fluorouracil.ti. and prodrug.ti.	4
<input type="checkbox"/>	L15	L13 and (fluorouracil.clm. or topotecan.clm. or irinotecan.clm. or 5-FU.clm.)	2
<input type="checkbox"/>	L14	L13 and (fluorouracil or camptothecin)	13
<input type="checkbox"/>	L13	L10 and (angiogenesis or vascul\$)	16
<input type="checkbox"/>	L12	L10 and ZD6126	1
<input type="checkbox"/>	L11	L10 and ZD6126.ab.	0
<input type="checkbox"/>	L10	angiogene.as.	17

END OF SEARCH HISTORY

FILE 'REGISTRY' ENTERED AT 09:16:11 ON 26 SEP 2007

EXP ZD6126/CN

L1 1 S IRINOTECAN/CN

L2 1 S FLUOROURACIL/CN

EXP CPT-11/CN

EXP CPT 11/CN

L3 1 S E3

EXP ZD 6126/CN

L4 1 S E3

FILE 'STNGUIDE' ENTERED AT 09:19:06 ON 26 SEP 2007

FILE 'HCAPLUS' ENTERED AT 09:20:55 ON 26 SEP 2007

L5 67 S L4/THU

L6 20014 S L1 OR L2 OR L3

L7 749941 S RADIATION

L8 24447 S COLORECTAL

L9 170 S (DIVIDED DOSE)

L10 5 S L5 AND L6

L11 1 S L5 AND L6 AND L7

L12 1 S L5 AND L6 AND L7 AND L8

FILE 'STNGUIDE' ENTERED AT 09:21:30 ON 26 SEP 2007

FILE 'HCAPLUS' ENTERED AT 09:23:11 ON 26 SEP 2007

L13 0 S L5 AND L8 AND L9

=> file registry		SINCE FILE	TOTAL
COST IN U.S. DOLLARS		ENTRY	SESSION
FULL ESTIMATED COST		0.42	0.42

FILE 'REGISTRY' ENTERED AT 09:16:11 ON 26 SEP 2007  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 SEP 2007 HIGHEST RN 948051-90-9  
 DICTIONARY FILE UPDATES: 25 SEP 2007 HIGHEST RN 948051-90-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

```
=> exp ZD6126/cn
E1      1      ZD52F10 PROTEIN (HUMAN CLONE IMAGE:3689908)/CN
E2      1      ZD52F10 PROTEIN (HUMAN CLONE IMAGE:3690018)/CN
E3      0 --> ZD6126/CN
E4      1      ZDA1/CN
E5      1      ZDA2/CN
E6      1      ZDA3/CN
E7      1      ZDA4/CN
E8      1      ZDBDC/CN
E9      1      ZDC/CN
E10     1      ZDC 2/CN
E11     1      ZDC1/CN
E12     1      ZDDMSE/CN
```

```
=> s irinotecan/cn
L1      1 IRINOTECAN/CN
```


```
=> s fluorouracil/cn
L2      1 FLUOROURACIL/CN
```

```
=> d 11 .
```

```
L1  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2007 ACS on STN
RN  97682-44-5  REGISTRY
ED  Entered STN: 18 Aug 1985
CN  [1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN  1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline, [1,4'-bipiperidine]-1'-carboxylic acid deriv.
CN  [1,4'-Bipiperidine]-1'-carboxylic acid, 4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester, (S)-
```

OTHER NAMES:  
 CN (+)-Irinotecan  
 CN Irinotecan  
 CN Irinotecan lactone  
 FS STEREOSEARCH  
 MF C33 H38 N4 O6  
 CI COM  
 SR CA  
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOSIS,  
                   CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU,  
                   IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MRCK\*, PATDPASPC, PROMT,  
                   PROUSDDR, PS, RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL  
                   (\*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2285 REFERENCES IN FILE CA (1907 TO DATE)  
 52 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 2317 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> exp cpt-11/cn
E1      1      CPT 223/CN
E2      1      CPT 224/CN
E3      0 --> CPT-11/CN
E4      1      CPT-B/CN
E5      1      CPT-L2-BA3/CN
E6      1      CPT1C PROTEIN (HUMAN CLONE MGC:9391 IMAGE:3872727)/CN
E7      1      CPT1C PROTEIN (MOUSE STRAIN CZECH II CLONE IMAGE:5039412)/CN
E8      2      CPTA/CN
E9      1      CPTA (LIGAND)/CN
E10     1      CPTA (PLANT GROWTH REGULATOR)/CN
E11     1      CPTC/CN
E12     1      CPTH/CN

=> exp cpt 11/cn
E1      1      CPSY PROTEIN (MYCOBACTERIUM TUBERCULOSIS STRAIN CDC1551 GENE
```


MT0826) /CN  
E2 3 CPT/CN  
E3 1 --> CPT 11/CN  
E4 1 CPT 11 CARBOXYLIC ACID/CN  
E5 1 CPT 1131/CN  
E6 1 CPT 154/CN  
E7 1 CPT 156/CN  
E8 1 CPT 160/CN  
E9 1 CPT 169/CN  
E10 1 CPT 170/CN  
E11 1 CPT 172/CN  
E12 1 CPT 175/CN

=> s E3  
L3 1 "CPT 11"/CN

=> d 13

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 100286-90-6 REGISTRY  
ED Entered STN: 15 Feb 1986  
CN [1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester, hydrochloride (1:1) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline, [1,4'-bipiperidine]-1'-carboxylic acid deriv.  
CN [1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester, monohydrochloride (9CI)  
CN [1,4'-Bipiperidine]-1'-carboxylic acid, 4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester, monohydrochloride, (S)-  
OTHER NAMES:  
CN 7-Ethyl-10-[[4-(1-piperidyl)-1-piperidyl]carbonyloxy]camptothecin hydrochloride  
CN Campto  
CN Camptosar  
CN Camptothecin 11  
CN Camptothecin 11 hydrochloride  
CN CPT 11  
CN Irinotecan hydrochloride  
CN Topotecin  
CN U 101440E  
FS STEREOSEARCH  
DR 111348-33-5  
MF C33 H38 N4 O6 . Cl H  
CI COM  
SR CA  
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IMSCOSEARCH, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK\*, PHAR, PROMT, PROUSDDR, PS, RTECS\*, SCISEARCH, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)  
CRN (97682-44-5)

Absolute stereochemistry. Rotation (+).



● HCl

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1035 REFERENCES IN FILE CA (1907 TO DATE)  
 15 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 1041 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> exp ZD 6126/cn
E1      1      ZD 5522/CN
E2      1      ZD 6021/CN
E3      1 --> ZD 6126/CN
E4      1      ZD 6169/CN
E5      1      ZD 6416/CN
E6      1      ZD 6474/CN
E7      1      ZD 6804/CN
E8      1      ZD 6888/CN
E9      1      ZD 7114/CN
E10     1      ZD 7155/CN
E11     1      ZD 7288/CN
E12     1      ZD 7717/CN


=> s E3
L4      1 "ZD 6126"/CN

=> d 14

L4      ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2007 ACS on STN
RN      219923-05-4  REGISTRY
ED      Entered STN: 23 Feb 1999
CN      Acetamide, N-[(5S)-6,7-dihydro-9,10,11-trimethoxy-3-(phosphonoxy)-5H-
dibenzo[a,c]cyclohepten-5-yl]- (CA INDEX NAME)
OTHER NAMES:
CN      ANG 453
```

CN AZD 6126  
 CN N-Acetylcolchicinol dihydrogenphosphate  
 CN ZD 6126  
 CN ZM 445526  
 FS STEREOSEARCH  
 MF C20 H24 N O8 P  
 CI COM  
 SR CA  
 LC STN Files: BIOSIS, CA, CAPLUS, CASREACT, EMBASE, IMSRESEARCH, IPA,  
     PROUSDDR, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

73 REFERENCES IN FILE CA (1907 TO DATE)  
 73 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file stnguide		SINCE FILE	TOTAL
COST IN U.S. DOLLARS		ENTRY	SESSION
FULL ESTIMATED COST		27.90	28.32

FILE 'STNGUIDE' ENTERED AT 09:19:06 ON 26 SEP 2007  
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
 LAST RELOADED: Sep 24, 2007 (20070924/UP).

=> file hcaplus		SINCE FILE	TOTAL
COST IN U.S. DOLLARS		ENTRY	SESSION
FULL ESTIMATED COST		0.18	28.50

FILE 'HCAPLUS' ENTERED AT 09:20:55 ON 26 SEP 2007  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Sep 2007 VOL 147 ISS 14  
FILE LAST UPDATED: 25 Sep 2007 (20070925/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L4/thu

L5            73 L4  
              937818 THU/RL  
              67 L4/THU  
              (L4 (L) THU/RL)

=> s L1 or l2 or l3

L6            2317 L1  
              18031 L2  
              1041 L3  
              20014 L1 OR L2 OR L3

=> s radiation

L7            749941 RADIATION

=> s colorectal

L8            24447 COLORECTAL

=> s (divided dose)

L9            183665 DIVIDED  
              615619 DOSE  
              170 (DIVIDED DOSE)  
              (DIVIDED (W)DOSE)

=> s 15 and 16

L10          5 L5 AND L6

=> s 15 and 16 and 17

L11          1 L5 AND L6 AND L7

=> s 15 and 16 and 17 and 18

L12          1 L5 AND L6 AND L7 AND L8

=> d 15 and 16 and 17 and 18 and 19

L6 IS NOT VALID HERE

For an explanation, enter "HELP DISPLAY".

=> file sntguide

'SNTGUIDE' IS NOT A VALID FILE NAME  
SESSION CONTINUES IN FILE 'HCAPLUS'

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

=> d 110 1-5 ti abs bib

L10 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI The x-ray crystal structure of BRCA1 tandem BRCT repeat and BACH1 phosphopeptide complex and methods and compositions for antitumor drug design  
AB The present invention relates to compds. (e.g., peptidomimetics and non-peptides) that treat, prevent or stabilize cellular proliferative disorders and methods of treating, preventing, or stabilizing such disorders. The invention also provides three-dimensional structures of a BRCT domain-BACH1 phosphopeptide complex.  
AN 2005:1290072 HCAPLUS <<LOGINID::20070926>>  
DN 144:46998  
TI The x-ray crystal structure of BRCA1 tandem BRCT repeat and BACH1 phosphopeptide complex and methods and compositions for antitumor drug design  
IN Yaffe, Michael B.; Clapperton, Julie A.; Manke, Isaac A.; Lowery, Drew M.; Ho, Timmy; Haire, Lesley F.; Smerdon, Stephen J.  
PA Massachusetts Institute of Technology, USA  
SO PCT Int. Appl., 360 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005115454	A2	20051208	WO 2005-US15981	20050509
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005247346	A1	20051208	AU 2005-247346	20050509
CA 2569003	A1	20051208	CA 2005-2569003	20050509
EP 1773389	A2	20070418	EP 2005-780060	20050509
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
PRAI US 2004-569131P	P	20040507		
WO 2005-US15981	W	20050509		

L10 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Human protein IAP (inhibitor of apoptosis protein) nucleobase oligomers, including dsRNA, shRNA, and siRNA, and their use for enhancing apoptosis in cancer therapy  
AB The invention provides nucleobase oligomers and oligonucleotide duplexes that inhibit expression of an IAP (inhibitor of apoptosis protein), and methods for using them to induce apoptosis in a cell. Specifically, the invention provides nucleic acid sequences for siRNAs and shRNAs that target human XIAP, HIAP-1 or HIAP-2 genes. The nucleobase oligomers and oligomer complexes of the present invention may also be used to form pharmaceutical compns. The invention also features methods for enhancing apoptosis in a cell by administering a nucleobase oligomer or oligomer complex of the invention in combination with a chemotherapeutic or chemosensitizing agent. RNAi sequences and vectors producing shRNA (short hairpin RNA) were transfected into HeLa cells and evaluated for their effect on XIAP, cIAP-1, or cIAP-2 protein levels. XIAP protein could also

be reduced by RNAi clones in transfected breast cancer cell line MDA-MB-231. In addition, cell survival was reduced in XIAP RNAi transfected breast cancer cell line after the transfected cells were treated with TRAIL (tumor necrosis factor-related apoptosis inducing ligand).

AN 2005:409543 HCAPLUS <<LOGINID::20070926>>

DN 142:457053

TI Human protein IAP (inhibitor of apoptosis protein) nucleobase oligomers, including dsRNA, shRNA, and siRNA, and their use for enhancing apoptosis in cancer therapy

IN Lacasse, Eric; McManus, Daniel

PA Aegera Therapeutics, Inc., Can.

SO PCT Int. Appl., 112 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005042558	A1	20050512	WO 2004-CA1902	20041029
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005148535	A1	20050707	US 2004-975974	20041028
	CA 2542904	A1	20050512	CA 2004-2542904	20041029
	EP 1682565	A1	20060726	EP 2004-789809	20041029
	R: DE, FR, GB				
	JP 2007510408	T	20070426	JP 2006-537024	20041029
PRAI	US 2003-516192P	P	20031030		
	WO 2004-CA1902	W	20041029		

L10 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Sequences of antisense IAP (inhibitor of apoptosis protein) oligomers and their use for treatment of proliferative diseases with a chemotherapeutic agent

AB The invention claims the use of an antisense oligomer to human XIAP, IAP-1 or IAP-2 genes and a chemotherapeutic agent, and compns. and kits thereof, for the treatment of proliferative diseases. The invention further claims sequences for nucleobase oligomers that are antisense IAP (inhibitor of apoptosis protein) oligomers. The antisense IAP nucleobase oligomers specifically hybridize with polynucleotides encoding an IAP and reduce the amount of an IAP protein produced in a cell. Thus by reducing the IAP protein, the invention provides methods for inducing cancer cells to undergo apoptosis and for overriding anti-apoptotic signals in cancer cells. As an example of the invention, mice with s.c. H460 human lung carcinoma xenografts were injected intratumorally with XIAP antisense mixed-base 2'-O-Me RNA oligonucleotides (C5 and/or G4) and the drug vinorelbine. At the end of the 24 d treatment period, the mean relative tumor growth was reduced .apprx.70% in treated mice. The inhibition of tumor growth was correlated with down-regulation of human XIAP protein expression and an increased number of dead cells. The mice did not show any signs of cytotoxicity such as body weight loss.

AN 2005:409357 HCAPLUS <<LOGINID::20070926>>

DN 142:457052

TI Sequences of antisense IAP (inhibitor of apoptosis protein) oligomers and their use for treatment of proliferative diseases with a chemotherapeutic agent

IN Lacasse, Eric; McManus, Daniel; Durkin, Jon P.  
 PA Aegera Therapeutics, Inc., Can.  
 SO PCT Int. Appl., 285 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005042030	A1	20050512	WO 2004-CA1900	20041029
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005119217	A1	20050602	US 2004-975790	20041028
	AU 2004284855	A1	20050512	AU 2004-284855	20041029
	CA 2542884	A1	20050512	CA 2004-2542884	20041029
	EP 1691842	A1	20060823	EP 2004-789807	20041029
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004015779	A	20061226	BR 2004-15779	20041029
	CN 1901939	A	20070124	CN 2004-80039601	20041029
	JP 2007509861	T	20070419	JP 2006-537023	20041029
	IN 2006MN00614	A	20070420	IN 2006-MN614	20060526
	NO 2006002420	A	20060731	NO 2006-2420	20060529
PRAI	US 2003-516263P	P	20031030		
	WO 2004-CA1900	W	20041029		

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Combinations of chlorpromazine compounds and antiproliferative drugs for  
the treatment of neoplasms  
 AB The invention discloses a method for treating a patient having a cancer or  
other neoplasm by administering chlorpromazine or a chlorpromazine analog  
and an antiproliferative agent simultaneously or within 14 days of each  
other in amts. sufficient to treat the patient.  
 AN 2005:283298 HCAPLUS <>LOGINID::20070926>>  
 DN 142:349042  
 TI Combinations of chlorpromazine compounds and antiproliferative drugs for  
the treatment of neoplasms  
 IN Lee, Margaret S.; Nichols, James M.; Zhang, Yanzhen; Keith, Curtis  
 PA Combinatorx, Incorporated, USA  
 SO PCT Int. Appl., 65 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005027842	A2	20050331	WO 2004-US30368	20040916
	WO 2005027842	A3	20051222		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,				
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,				
SN, TD, TG				
US 2004154316	A1	20040812	US 2003-359834	20030207
CA 2515188	A1	20040826	CA 2004-2515188	20040203
WO 2004072913	A2	20040826	WO 2004-US3021	20040203
WO 2004072913	A3	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,				
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,				
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1590776	A2	20051102	EP 2004-707767	20040203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004007281	A	20060131	BR 2004-7281	20040203
CN 1754192	A	20060329	CN 2004-80005053	20040203
AU 2004273910	A1	20050331	AU 2004-273910	20040916
CA 2538570	A1	20050331	CA 2004-2538570	20040916
EP 1670477	A2	20060621	EP 2004-788798	20040916
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004014568	A	20061107	BR 2004-14568	20040916
CN 1878556	A	20061213	CN 2004-80033294	20040916
JP 2007505914	T	20070315	JP 2006-527024	20040916
MX 2005PA08325	A	20060228	MX 2005-PA8325	20050805
MX 2006PA03066	A	20060620	MX 2006-PA3066	20060317
NO 2006001325	A	20060606	NO 2006-1325	20060323
KR 2007012618	A	20070126	KR 2006-707244	20060414
PRAI US 2003-504310P	P	20030918		
US 2003-359834	A	20030207		
WO 2004-US3021	W	20040203		
WO 2004-US30368	W	20040916		
OS MARPAT 142:349042				

L10 ANSWER 5 OF 5 HCPLUS COPYRIGHT 2007 ACS on STN  
 TI Combination cancer therapy using ZD6126 with 5-FU and/or CPT-11  
 AB The invention discloses a method for the production of a vascular-damaging effect in a warm-blooded animal, e.g. a human, which is optionally being treated with ionizing radiation, particularly a method for the treatment of a cancer involving a solid tumor, e.g. colorectal cancer, which comprises one of: the administration of ZD6126 in combination with 5-FU; the administration of ZD6126 in combination with CPT-11; and the administration of ZD6126 in combination with 5-FU and CPT-11. Also claimed are pharmaceutical compns. and kits comprising one of: ZD6126 and 5-FU; ZD6126 and CPT-11; and ZD6126 and 5-FU and CPT-11; and the use of one of: ZD6126 and 5-FU; ZD6126 and CPT-11; and ZD6126 and 5-FU and CPT-11, in the manufacture of a medicament for use in the production of a vascular-damaging effect in a warm-blooded animal which is optionally being treated with ionizing radiation.

AN 2004:1156504 HCPLUS <>LOGINID::20070926>>  
 DN 142:69168  
 TI Combination cancer therapy using ZD6126 with 5-FU and/or CPT-11  
 IN Ryan, Anderson Joseph  
 PA Angiogene Pharmaceuticals Limited, UK  
 SO PCT Int. Appl., 30 pp.  
 CODEN: PIXXD2  
 DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004112801	A2	20041229	WO 2004-GB2624	20040618
	WO 2004112801	A3	20050324		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004248968	A1	20041229	AU 2004-248968	20040618
	CA 2529409	A1	20041229	CA 2004-2529409	20040618
	EP 1658084	A2	20060524	EP 2004-742979	20040618
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR			
	BR 2004011567	A	20060801	BR 2004-11567	20040618
	CN 1835757	A	20060920	CN 2004-80023133	20040618
	JP 2006527753	T	20061207	JP 2006-516444	20040618
	NO 2005005888	A	20060316	NO 2005-5888	20051212
	MX 2005PA13827	A	20060313	MX 2005-PA13827	20051216
	US 2006142239	A1	20060629	US 2005-561183	20051216
PRAI	GB 2003-14097	A	20030618		
	GB 2003-16181	A	20030710		
	WO 2004-GB2624	W	20040618		

=> file stnguide

COST IN U.S. DOLLARS

SINCE FILE

FULL ESTIMATED COST

ENTRY

TOTAL

SESSION

16.75

45.25

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

CA SUBSCRIBER PRICE

ENTRY

TOTAL

SESSION

-3.90

-3.90

FILE 'STNGUIDE' ENTERED AT 09:21:30 ON 26 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Sep 24, 2007 (20070924/UP).

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

FULL ESTIMATED COST

ENTRY

TOTAL

SESSION

0.18

45.43

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

CA SUBSCRIBER PRICE

ENTRY

TOTAL

SESSION

0.00

-3.90

FILE 'HCAPLUS' ENTERED AT 09:23:11 ON 26 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Sep 2007 VOL 147 ISS 14  
FILE LAST UPDATED: 25 Sep 2007 (20070925/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 15 and 18 and 19

L13 0 L5 AND L8 AND L9

=> d l11 ti

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Combination cancer therapy using ZD6126 with 5-FU and/or CPT-11

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.94	48.37
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.90

FILE 'STNGUIDE' ENTERED AT 09:23:14 ON 26 SEP 2007  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Sep 24, 2007 (20070924/UP).

=> d his